References
- Opatrny L, Dell’Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169–175; discussion 175.
- Sitruk-Ware R.Routes of delivery for progesterone and progestins. Maturitas 2007;57:77–80.
- Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003;10:13–18.
- Elshafie MA, Ewies AA. Transdermal natural progesterone cream for postmenopausal women: inconsistent data and complex pharmacokinetics. J Obstet Gynaecol 2007;27:655–659.
- Fugh-Berman A, Bythrow J. Bioidentical hormones for menopausal hormone therapy: Variation on a theme. J Gen Intern Med 2007;22:1030–1034.
- Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603–618.
- Lopes LB, Collett JH, Bentley MV. Topical delivery of cyclosporin A: An in vitro study using monoolein as a penetration enhancer. Eur J Pharm Biopharm 2005;60:25–30.
- Karande P, Jain A, Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol 2004;22:192–197.
- Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm 2009; 71:310–7.
- Constantinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H, Smith PL. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res 1994;11:1385–1390.
- Furuishi T, Oda S, Saito H, Fukami T, Suzuki T, Tomono K. Effect of permeation enhancers on the in vitro percutaneous absorption of pentazocine. Biol Pharm Bull 2007;30:1350–1353.
- Herai H, Gratieri T, Thomazine JA, Bentley MV, Lopez RF. Doxorubicin skin penetration from monoolein-containing propylene glycol formulations. Int J Pharm 2007;329:88–93.
- Wagner H, Kostka KH, Adelhardt W, Schaefer UF. Effects of various vehicles on the penetration of flufenamic acid into human skin. Eur J Pharm Biopharm 2004;58:121–129.
- Morgan TM, Reed BL, Finnin BC. Enhanced skin permeation of sex hormones with novel topical spray vehicles. J Pharm Sci 1998;87:1213–1218.
- Verhulst C, Coiffard C, Coiffard LJ, Rivalland P, De Roeck-Holtzhauer Y. In vitro correlation between two colorimetric assays and the pyruvic acid consumption by fibroblasts cultured to determine the sodium laurylsulfate cytotoxicity. J Pharmacol Toxicol Meth 1998;39:143–146.
- Cal K. Skin penetration of terpenes from essential oils and topical vehicles. Planta Med 2006;72:311–316.
- Oh SY, Jeong SY, Park TG, Lee JH. Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer. J Control Release 1998;51:161–168.
- Biruss B, Kahlig H, Valenta C. Evaluation of a eucalyptus oil containing topical drug delivery system for selected steroid hormones. Int J Pharm 2007;328:142–151.
- Biruss B, Valenta C. The advantage of polymer addition to a non-ionic oil in water microemulsion for the dermal delivery of progesterone. Int J Pharm 2008;349:269–273.
- Mitragotri S, Edwards DA, Blankschtein D, Langer R. A mechanistic study of ultrasonically-enhanced transdermal drug delivery. J Pharm Sci 1995;84:697–706.
- Benavides T, Mitjans M, Martinez V, Clapes P, Infante MR, Clothier RH, Vinardell MP. Assessment of primary eye and skin irritants by in vitro cytotoxicity and phototoxicity models: An in vitro approach of new arginine-based surfactant-induced irritation. Toxicology 2004;197:229–237.
- Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial 2007;20:217–219.